Announcements Trials
Browse Landscape

Status

No longer available 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 47Observational 3Expanded_access 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Sarcoma 2

Interventions

tazemetostat 2regorafenib 2nirogacestat 2avapritinib 2Trabectedin 2selinexor 1ripretinib 1omburtamab I-131 1olaratumab 1mifamurtide 1glucarpidase 1ganitumab 1fludarabine phosphate 1balstilimab 1anlotinib 1Whole-Body Irradiation 1Tacrolimus 1TH 302 1Sunitinib 1Proton Pump Inhibitors 1Mycophenolic Acid 1Imatinib Mesylate 1Hydrocortisone 1FANG vaccine 1Everolimus 1DOXO-EMCH 1Cytarabine 1Cord Blood Stem Cell Transplantation 1Carboxypeptidases 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × Trabectedin × Sarcoma × Clear all
NCT00210665 2017-10-10

A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

Janssen Research & Development, LLC

No longer available
Sarcoma

Sarcoma

NCT01427582 2011-09-01

YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access

University of Texas Southwestern Medical Center

No longer available
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡